中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
19期
28-30
,共3页
泮托拉唑%曲美布汀%氟哌噻吨美利曲辛片%胃食管反流病
泮託拉唑%麯美佈汀%氟哌噻噸美利麯辛片%胃食管反流病
반탁랍서%곡미포정%불고새둔미리곡신편%위식관반류병
Pantoprazole%Trimebutine%Flupentixol and Melitracen tablets%Gastroesophageal reflux disease
目的：探讨泮托拉唑、曲美布汀联合氟哌噻吨美利曲辛片治疗胃食管反流病的临床疗效。方法：选取2012年1月-2013年10月本院收治的胃食管反流病患者120例，按患者自愿原则分为试验组63例和对照组57例，试验组采用泮托拉唑、曲美布汀联合氟哌噻吨美利曲辛片治疗；对照组予泮托拉唑和曲美布汀治疗，疗程均为4周。比较两组患者的临床治疗效果、停药3个月后复发率及不良反应发生率。结果：试验组总有效率高于对照组，差异有统计学意义（P<0.05）；停药3个月后试验组复发率低于对照组，差异有统计学意义（P<0.05）；治疗后试验组SAS、SDS值均明显降低，与对照组比较差异均有统计学意义（P<0.01）；治疗过程中两组均未发生明显不良反应。结论：泮托拉唑、曲美布汀联合氟哌噻吨美利曲辛片治疗胃食管反流病能有效改善临床症状，并能有效预防其复发，疗效显著，值得临床中推广应用。
目的：探討泮託拉唑、麯美佈汀聯閤氟哌噻噸美利麯辛片治療胃食管反流病的臨床療效。方法：選取2012年1月-2013年10月本院收治的胃食管反流病患者120例，按患者自願原則分為試驗組63例和對照組57例，試驗組採用泮託拉唑、麯美佈汀聯閤氟哌噻噸美利麯辛片治療；對照組予泮託拉唑和麯美佈汀治療，療程均為4週。比較兩組患者的臨床治療效果、停藥3箇月後複髮率及不良反應髮生率。結果：試驗組總有效率高于對照組，差異有統計學意義（P<0.05）；停藥3箇月後試驗組複髮率低于對照組，差異有統計學意義（P<0.05）；治療後試驗組SAS、SDS值均明顯降低，與對照組比較差異均有統計學意義（P<0.01）；治療過程中兩組均未髮生明顯不良反應。結論：泮託拉唑、麯美佈汀聯閤氟哌噻噸美利麯辛片治療胃食管反流病能有效改善臨床癥狀，併能有效預防其複髮，療效顯著，值得臨床中推廣應用。
목적：탐토반탁랍서、곡미포정연합불고새둔미리곡신편치료위식관반류병적림상료효。방법：선취2012년1월-2013년10월본원수치적위식관반류병환자120례，안환자자원원칙분위시험조63례화대조조57례，시험조채용반탁랍서、곡미포정연합불고새둔미리곡신편치료；대조조여반탁랍서화곡미포정치료，료정균위4주。비교량조환자적림상치료효과、정약3개월후복발솔급불량반응발생솔。결과：시험조총유효솔고우대조조，차이유통계학의의（P<0.05）；정약3개월후시험조복발솔저우대조조，차이유통계학의의（P<0.05）；치료후시험조SAS、SDS치균명현강저，여대조조비교차이균유통계학의의（P<0.01）；치료과정중량조균미발생명현불량반응。결론：반탁랍서、곡미포정연합불고새둔미리곡신편치료위식관반류병능유효개선림상증상，병능유효예방기복발，료효현저，치득림상중추엄응용。
Objective:To observe clinical curative effect of Pantoprazole, Trimebutine combined with Flupentixol and Melitracen tablets in the treatment of gastroesophageal reflux disease.Method:120 cases of gastroesophageal reflux disease in our hospital from January 2012 to October 2013 were selected, and they were divided into the experimental group for 63 cases and the control group for 57 cases according to the patients with voluntary basis. The experimental group was treated with Pantoprazole, Trimebutine combined with Flupentixol and Melitracen tablets; the control group was given Pantoprazole, Trimebutine, a course of 4 weeks. The clinical therapeutic effect and drug withdrawal after 3 months,the recurrence rate and adverse reactions were compared between the two groups.Result:The total effective rate of the experimental group was higher than the control group, the difference was statistically significant (P<0.05); Withdrawal after 3 months, the recurrence rate of the experimental group was lower than the control group, the difference was statistically significant(P<0.05); after treatment, SAS, SDS value of the experimental group were significantly lower, compared with the control group were statistically significant difference (P<0.01); patients of the two groups had no obvious adverse reaction in treatment.Conclusion: Pantoprazole, Trimebutine combined with Flupentixol and Melitracen tablets in the treatment of gastroesophageal reflux disease can effectively improve the clinical symptoms, and can effectively prevent its recurrence, curative effect is distinct, is worth popularizing in clinical application.
